NewAmsterdam Pharma to Present Alzheimer’s Biomarker Data from BROADWAY Trial at AAIC 2025

Core Insights - NewAmsterdam Pharma will present full data from the Alzheimer's Disease biomarker analyses in the BROADWAY clinical trial at the Alzheimer's Association International Conference on July 30, 2025 [1] - The presentation will focus on the effects of Obicetrapib, a potent oral CETP inhibitor, on Alzheimer's Disease biomarkers in 1,727 patients with cardiovascular disease [2] Company Overview - NewAmsterdam Pharma is a late-stage clinical biopharmaceutical company focused on developing oral, non-statin medicines for patients at risk of cardiovascular disease with elevated LDL-C [1][6] - The company aims to address unmet needs for safe and well-tolerated LDL-lowering therapies [6][7] Product Information - Obicetrapib is a novel, oral, low-dose CETP inhibitor developed by NewAmsterdam to improve LDL-lowering treatment outcomes [5] - The company has conducted multiple Phase 2 and Phase 3 trials, demonstrating statistically significant LDL-lowering effects with a side effect profile similar to placebo [5][7] - The Phase 3 PREVAIL cardiovascular outcomes trial, which began in March 2022, has enrolled over 9,500 patients to assess the potential of obicetrapib in reducing major adverse cardiovascular events (MACE) [5] Conference Details - The live webcast and conference call to review the full AD biomarker data will take place on July 30, 2025, at 10:00 a.m. ET [1][4] - The presentation will be led by Philip Scheltens, M.D., Ph.D., and will occur from 8:21 to 8:28 AM ET [2]